Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

Molecular testing in lung cancer is crucial, Hirsch explains. With the development of personalized medicine, it is important to map a tumor's molecular characteristics, as this has significant clinical implications for many patients. This continues to be an evolving field, he adds.

Over recent years, a collaboration between three organizations has led to the development of a set of evidence-based guidelines for molecular testing. 

View more from the 2016 International Lung Cancer Congress

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Hirsch on Importance of Molecular Testing in Lung Cancer